Grifols signs deal to license Aradigm's Pulmaquin
MADRID May 21 (Reuters) - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.
Pulmaquin is a dual release ciprofloxacin for inhalation in non-cystic fibrosis bronchiectasis.
In a regulatory filing, Grifols said it will invest up to $65 million to help develop the compound and may spend $25.7 million to buy a 35 percent stake in Aradigm through a capital hike at the U.S. firm, which posted a net loss in the first quarter.
- Police seek motive in fatal Washington state school shooting
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Two deputies killed, two others hurt in California shooting spree
- Wall St. finally turning on Amazon as Bezos magic fades
- U.S., allies stage 22 air strikes in Iraq: U.S. Central Command